Parnax Lab Ltd (PARNAXLAB) — shareholding pattern, promoter holding, financials and share price
About Parnax Lab Ltd (PARNAXLAB)
Parnax Lab Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PARNAXLAB and on the BSE under scrip code 506128. Its ISIN is INE383L01019.
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations [1]
Parnax Lab Limited, formerly Krishna Deep Trade & Investment Ltd, was incorporated in 1982 and is engaged in manufacturing and exporting pharmaceutical formulations.
Naxpar Pharma Private Limited, a subsidiary, has over two decades of expertise in pharmaceuticals and is acclaimed for innovation in cosmetics, herbal formulations, and nutraceuticals.
Listed peers in Pharmaceuticals: Sanjivani Paranteral Ltd, Accretion Pharmaceuticals Ltd, Bio Medica Laboratories Ltd, Panchsheel Organics Ltd, Speciality Medicines Ltd, Auro Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹142.7 a share on 10 Jul 2026, Parnax Lab Ltd (PARNAXLAB) was valued at a price-to-earnings ratio of 13.9x against an industry P/E of 36.41x and a price-to-book of 1.97x on a book value of ₹72.35 per share as of Mar 2025. Solomo computes return on equity of 14.19% and return on capital employed of 14.16% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 13.9x
- Industry P/E
- 36.41x
- P/B
- 1.97x
- EPS (TTM)
- ₹10.27
- Book value / share
- ₹72.35
- ROE
- 14.19%
- ROCE
- 14.16%
- ROA
- 6.21%
- Debt / equity
- 0.84x
- Dividend yield
- 0%
- EBITDA margin
- 11.93%
- 52-week range
- ₹142.7 – ₹145
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Parnax Lab Ltd (PARNAXLAB) reported revenue of ₹249 crore, net profit of ₹12 crore and earnings per share of ₹10.26. That compares with revenue of ₹188 crore and net profit of ₹12 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹69.63 crore and net profit ₹2.19 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 163 | 168 | 189 | 188 | 249 |
| Net profit (₹ cr) | 8 | 9 | 10 | 12 | 12 |
| EPS (₹) | 8.4 | 7.51 | 8.37 | 10.03 | 10.26 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.38% | -1.78% | -0.61% | -0.51% |
| Profit growth | - | - | 37.07% | 19.96% |
| Stock price CAGR | 16% | 43% | 28% | 36% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.3% of Parnax Lab Ltd (PARNAXLAB) (unchanged from the previous quarter). Promoters have pledged 9.4% of their holding. Market capitalisation was ₹164 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2001.
Largest disclosed public shareholders in Jun 2026: Suman Gupta 1.62%, Tradelink Exim India Private Limited 1.35%, HUF 1.34%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.3% | 9.4% | - | - | 27.7% |
| Mar 2026 | 72.3% | 9.4% | - | - | 27.7% |
| Dec 2025 | 72.3% | 9.4% | - | - | 27.7% |
| Sep 2025 | 72.3% | 9.4% | - | - | 27.7% |
| Jun 2025 | 72.3% | 9.4% | - | - | 27.7% |
| Mar 2025 | 72.3% | 9.4% | - | - | 27.7% |
| Dec 2024 | 72.3% | 9.4% | - | - | 27.7% |
| Sep 2024 | 72.3% | 9.4% | - | - | 27.7% |